Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($1.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.24, Zacks reports.
Tectonic Therapeutic Stock Up 1.3%
TECX stock traded up $0.26 during midday trading on Friday, hitting $19.68. The company’s stock had a trading volume of 17,570 shares, compared to its average volume of 254,329. The stock has a market cap of $384.69 million, a price-to-earnings ratio of -4.29 and a beta of 3.51. The stock’s 50-day moving average price is $24.61 and its 200 day moving average price is $27.99. Tectonic Therapeutic has a 1 year low of $16.77 and a 1 year high of $39.53.
Analyst Ratings Changes
TECX has been the subject of several analyst reports. TD Cowen reiterated a “buy” rating on shares of Tectonic Therapeutic in a report on Wednesday, September 30th. Wall Street Zen cut shares of Tectonic Therapeutic from a “sell” rating to a “strong sell” rating in a report on Sunday, October 18th. Wells Fargo & Company reduced their price objective on shares of Tectonic Therapeutic from $101.00 to $93.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. Zacks Research raised shares of Tectonic Therapeutic from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 18th. Finally, UBS Group initiated coverage on shares of Tectonic Therapeutic in a research note on Sunday, October 11th. They issued a “neutral” rating and a $26.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $69.17.
Get Our Latest Research Report on Tectonic Therapeutic
About Tectonic Therapeutic
Tectonic Therapeutic, Inc is a clinical-stage biotechnology company focused on developing medicines that target G protein-coupled receptors (GPCRs), a large class of cell-surface proteins involved in numerous biological processes and diseases. The company seeks to address GPCRs that have historically been difficult to target with conventional drug-discovery methods.
Tectonic Therapeutic uses its proprietary GEODe platform to identify and develop antibodies and other biologic medicines against GPCRs.
Read More
- Five stocks we like better than Tectonic Therapeutic
- Arista Networks Cashes In on the AI Infrastructure Buildout
- Powering Up: Freeport-McMoRan’s $4.5B Copper Expansion
- 3 Dividend ETFs Offer Different Ways to Navigate the Post-Election Sell-Off
- Riot’s $28B Lease Shows Why Location and Contracts Matter in AI
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.
